Profile data is unavailable for this security.
About the company
Changchun BCHT Biotechnology Co is a China-based innovative biomedical company mainly dedicated to the prevention and treatment of infectious diseases. The Company is mainly engaged in the research and development, production and sales of human vaccines. The Company has three approved vaccine products: varicella vaccine, rabies vaccine and freeze-dried nasal spray flu vaccine. The Company also has other vaccines under development and fully human monoclonal antibody under development for the prevention and control of infectious diseases. The Company mainly conducts business within the domestic market.
- Revenue in CNY (TTM)1.88bn
- Net income in CNY527.23m
- Incorporated2004
- Employees1.24k
- LocationChangchun BCHT Biotechnology CoNo. 138Zhuoyue Street, Chaoyang DistrictCHANGCHUN 130103ChinaCHN
- Phone+86 43 181871543
- Fax+86 43 181871549
- Websitehttp://www.bchtpharm.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zhejiang Hisun Pharmaceutical Co., Ltd. | 9.56bn | -77.34m | 8.50bn | 8.06k | -- | 1.05 | -- | 0.8898 | -0.0788 | -0.0788 | 8.09 | 6.72 | 0.5421 | 3.36 | 4.06 | 1,185,368.00 | -0.5337 | 1.95 | -0.8961 | 3.77 | 38.03 | 40.58 | -0.9846 | 3.43 | 0.6209 | 2.46 | 0.397 | 26.07 | -13.82 | 0.3618 | -119.05 | -- | -31.58 | -- |
| Changchun BCHT Biotechnology Co | 1.88bn | 527.23m | 9.06bn | 1.24k | 17.16 | 2.20 | -- | 4.81 | 1.28 | 1.28 | 4.56 | 9.96 | 0.394 | 0.7747 | 1.53 | 1,517,684.00 | 11.03 | 9.95 | 13.51 | 12.81 | 89.44 | 86.63 | 27.99 | 24.03 | 1.99 | -- | 0.0252 | 10.55 | 70.30 | 12.36 | 175.98 | 31.37 | 21.04 | -- |
| Mayinglong Pharmaceutical Group Co Ltd | 3.42bn | 473.79m | 9.28bn | 2.88k | 19.58 | 2.41 | -- | 2.71 | 1.10 | 1.10 | 7.94 | 8.94 | 0.6648 | 6.05 | 10.01 | 1,188,102.00 | 9.35 | 10.82 | 11.58 | 13.47 | 43.86 | 41.18 | 14.07 | 14.08 | 4.06 | -- | 0.0946 | 33.04 | -11.20 | 7.38 | -7.46 | 20.26 | 58.33 | 21.67 |
| KPC Pharmaceuticals Inc | 7.49bn | 450.79m | 9.28bn | 5.05k | 20.64 | 1.73 | -- | 1.24 | 0.594 | 0.594 | 9.89 | 7.10 | 0.7847 | 2.43 | 2.66 | 1,482,262.00 | 4.79 | 5.42 | 8.10 | 9.13 | 41.97 | 43.68 | 6.11 | 5.70 | 1.44 | -- | 0.199 | 35.75 | -6.99 | 1.64 | 16.05 | 5.79 | -21.33 | 14.87 |
| Liaoning Chengda Biotechnology Co Ltd | 1.76bn | 352.53m | 9.39bn | 1.73k | 26.73 | 0.9833 | -- | 5.34 | 0.8438 | 0.8438 | 4.23 | 22.93 | 0.1766 | 0.7386 | 1.48 | 1,015,870.00 | 3.54 | 10.63 | 3.66 | 11.01 | 81.24 | 85.74 | 20.04 | 39.56 | 17.34 | -- | 0.0019 | 31.53 | -3.58 | 4.71 | -34.75 | -5.56 | 39.78 | -- |
| Heilongjiang ZBD Pharmaceutical Co Ltd | 2.22bn | 522.07m | 9.44bn | 2.55k | 18.03 | 1.19 | -- | 4.26 | 0.5556 | 0.5556 | 2.36 | 8.43 | 0.1757 | 0.6759 | 0.6464 | 870,758.90 | 4.10 | 3.48 | 5.54 | 4.78 | 64.84 | 38.93 | 23.37 | 10.08 | 2.18 | -- | 0.2951 | 27.18 | -25.50 | 2.45 | 155.00 | 0.4417 | -25.68 | 4.05 |
Data as of Sep 13 2024. Currency figures normalised to Changchun BCHT Biotechnology Co's reporting currency: Chinese Yuan Renminbi CNY
5.75%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| China Merchants Fund Management Co., Ltd.as of 31 Dec 2023 | 5.63m | 1.36% |
| E Fund Management Co., Ltd.as of 30 Jun 2024 | 5.53m | 1.34% |
| Penghua Fund Management Co., Ltd.as of 31 Dec 2023 | 2.23m | 0.54% |
| Guotai Asset Management Co., Ltd.as of 31 Dec 2023 | 2.15m | 0.52% |
| GF Fund Management Co., Ltd.as of 31 Dec 2023 | 2.00m | 0.48% |
| China Southern Asset Management Co., Ltd.as of 31 Dec 2023 | 1.71m | 0.41% |
| Bosera Asset Management Co., Ltd.as of 31 Dec 2023 | 1.64m | 0.40% |
| Invesco Great Wall Fund Management Co. Ltd. (Invt Mgmt)as of 31 Dec 2023 | 1.02m | 0.25% |
| Minsheng Royal Fund Management Co., Ltd.as of 31 Dec 2023 | 948.95k | 0.23% |
| Tian Hong Asset Management Co., Ltd.as of 31 Dec 2023 | 912.59k | 0.22% |
More ▼
Data from 31 Dec 2023 - 12 Sep 2024Source: FactSet Research Systems Inc.
